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ABSTRACT
Objectives: The present study was designed to investigate the antioxidant and anti-arthritic activities of azathioprine-pioglitazone combination 
therapy to check whether it has an add on benefit over monotherapy with azathioprine or pioglitazone on disease activity in rodent models.
Methods: The antioxidant activity of test drugs and their combination was screened by H2O2 and nitric oxide scavenging assays. They were further 
evaluated for anti-arthritic activity using in vitro models such as protein denaturation and membrane stabilization and in vivo methods such as 
formaldehyde and complete Freund’s adjuvant (CFA)-induced arthritis.
Results: The combination of test drugs showed better inhibition of free radicals in both H2O2 and nitric oxide scavenging assay than individual 
counterparts revealing its potential antioxidant activity. They also showed significant inhibition of protein denaturation and proliferation of the red 
blood cell in in vitro models. The test drugs showed significant inhibition of the paw volume in both the formaldehyde and CFA-induced arthritis along 
with reverting the altered biochemical parameters. These findings were corroborated by radiological and histopathological studies.
Conclusions: Combination of azathioprine and pioglitazone exhibited better antioxidant and anti-arthritic effect than the individual drugs showing 
synergistic interaction between them.
Keywords: Azathioprine, Pioglitazone, Arthritis, Formaldehyde, Complete Freund’s adjuvant.
INTRODUCTION
Free radicals or reactive oxygen species (ROS) are highly unstable 
molecules produced during normal cellular metabolism by living 
organisms [1]. Imbalance between oxidants and antioxidants is termed 
as “oxidative stress” [2]. Oxidative stress is the predominant predisposing 
factors of diseases such as cancer, diabetes, rheumatoid arthritis (RA), 
and neurodegenerative disorders. Hydrogen peroxide and nitric oxide 
are the major free radicals which are involved in the development of 
autoimmune disorders such as RA and systemic lupus erythematosus [3].
RA is a chronic and systemic autoimmune joint disease that is characterized 
by non-specific inflammation of peripheral joints and destruction of 
cartilage and bone with resultant disability [4]. RA affects 0.5%–1% of 
adults in industrialized countries. Its incidence and prevalence are higher 
in women than in men, and in older adults than in younger ones [5,6]. 
Tumor necrosis factor (TNF)-α, interleukin (IL)-1 β, and IL-6 are major 
proinflammatory cytokines that play a key role in the pathological process 
of RA [7]. Its typical pathological findings are synovial hyperplasia, 
inflammatory cell infiltration, pannus formation, articular cartilage 
damage, bone erosion as well as extra-articular manifestations [8,9]. Joint 
swelling, joint pain, reduced ability to move the joint, redness of the skin 
around a joint, and morning stiffness are the symptoms of RA [5]. Disease-
modifying antirheumatic drugs, nonsteroidal anti-inflammatory drugs, 
corticosteroids, and biologic drugs are the main agents used to treat RA in 
the current clinic. However, lack of optimum efficacy and potential safety 
concerns limit their long-term use as monotherapy in RA, and therefore, 
combination therapy is recommended [10,11].
Azathioprine constitutes a mainstay in the therapy of RA. Its suggested 
mechanisms include (i) inhibition of DNA synthesis, (ii) inhibition of 
clonal proliferation during the induction phase of the immune response, 
and (iii) suppression of cell-mediated and antibody-mediated immune 
reactions [12].
Pioglitazone, an oral antidiabetic agent, acts as a ligand for peroxisome 
proliferator-activated receptor gamma. It suppresses the production 
of inflammatory cytokines and matrix metalloproteinases [13] and 
causes inhibition of proinflammatory gene expression [14]. Further, 
it causes induction of apoptosis in macrophages and T-lymphocytes 
which are vital in perpetuating the RA disease progress [15,16]. Some 
experiments have shown the efficacy of pioglitazone in preclinical 
arthritic models.
For both azathioprine and pioglitazone exert anti-inflammatory actions 
in inflamed joints through different mechanisms, it was assumed 
that azathioprine and pioglitazone combination therapy might have 
synergistic efficacy in patients with RA.
In the above context, the present study was conducted to explore add 
on the benefit of azathioprine and pioglitazone combination therapy 




Azathioprine was purchased from Rakshit Drugs Private Limited, 
Hyderabad. Pioglitazone was purchased from Hetero Drugs Limited, 
Hyderabad. Chemicals and reagents used were of analytical grade. 
Complete Freund’s adjuvant (CFA) was procured from Sigma-Aldrich 
Corporation, Mumbai.
Animals
Wistar albino rats (Approx. 150–200 g) were procured from Albino 
research, Hyderabad. The care and maintenance of the animals were 
carried out as per the approved guidelines of the Committee for 
the Purpose of Control and Supervision of Experiments on Animals 
(Registration number: 1175/PO/Re/S/08/CPCSEA).
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i3.30902
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Methods
In vitro antioxidant assays
Hydrogen peroxide radical scavenging assay
A solution of hydrogen peroxide (40 mM) was prepared in phosphate 
buffer (pH 7.4). Drugs at the concentration of 10 mg/10 µL were added 
to 0.6 mL of H2O2 solution. The total volume was made up to 3 mL with 
phosphate buffer. The absorbance of the reaction mixture was recorded at 
230 nm. The blank solution contained phosphate buffer without H2O2 [17].
Hydrogen peroxide activity (%) = Abs control − Abs sample/Abs control × 100
Nitric oxide scavenging activity
Nitric oxide scavenging activity can be estimated using Griess-ilosvay 
reaction. Nitric oxide scavenging activity was measured using a 
spectrophotometer. Drug was prepared in DMSO, was added to different 
test tubes in varying concentrations sodium nitroprusside (5 mM) in 
phosphate buffer was added to each test tube to make volume up to 
1.5 mL. Solutions were incubated at 25°C for 30 min. Add 1.5 mL of 
Griess reagent (1% sulfanilamide, 0.1% naphthyl ethylenediamine 
dichloride, and 3% phosphoric acid) was added to each test tube. The 
absorbance was measured, immediately, at 546 nm and the percentage 
of scavenging activity was measured with reference to ascorbic acid as 
standard [18].
Nitric oxide scavenging activity (%) =Abs control − Abs sample/Abs 
control × 100
In vitro evaluation of anti-arthritic activity
Inhibition of protein denaturation method
The reaction mixture (0.5 mL) consisted of 0.45 mL bovine serum 
albumin (5% aqueous solution) and 0.05 mL of test drugs (100 and 
200 µg/mL of final volume). pH was adjusted to 6.3 using a small amount 
of 1 N HCl. The samples were incubated at 37°C for 20 min and then 
heated at 57°C for 3 min. After cooling the samples, 2.5 mL phosphate 
buffer saline (pH 6.3) was added to each tube. Turbidity was measured 
spectrophotometrically at 660 nm. For control tests, 0.05 mL distilled 
water was used instead of test drug [19]. The percentage inhibition of 
protein denaturation was calculated as follows:
Percentage inhibition = 100 × 1 – (absorbance of test sample/absorbance 
of control).
Membrane stabilization method
Fresh rat blood was collected into a centrifuge tube containing 0.5 mL of 
200 mM ethylenediaminetetraacetic acid. The tubes were centrifuged 
at 3000 rpm for 15 min and washed thrice with an equal volume of 
normal saline. The volume of red blood cell (RBC) was measured and 
reconstituted as 10% v/v suspension with normal saline [20].
Hypotonic solution induced hemolysis
The reaction mixtures (4.5 mL) consisted of 2 mL hypotonic saline 
(0.25% NaCl), 1 mL of 0.15 M phosphate buffer (pH 7.4), and 1 mL test 
solution (100 and 200 µg/mL of final volume) in normal saline. 0.5 mL 
of 10% rat RBC in normal saline was added. For control tests, 1 mL of 
isotonic saline was used instead of the test solution. The mixtures were 
incubated at 56°C for 30 min. The tubes were cooled under running 
tap water for 20 min. The mixtures were centrifuged and the optical 
density of the supernatants read at 560 nm [21]. The percent inhibition 
was calculated.
Percent inhibition = 100 × 1 – (absorbance of test sample/absorbance 
of control).
In vivo evaluation of anti-arthritic activity
Formaldehyde-induced arthritis
Paw edema in the right foot of rats was induced by subplantar injection 
of 0.1 mL of 2% freshly prepared formaldehyde on day 1 and 3 of the 
experiment to model chronic arthritis. Formaldehyde was injected 30 min 
after drug dosing. One of the two treatments was given to the animals orally 
once per day for the duration of the experiment. Paw volume was measured 
initially and then on days 3, 5, 7, 9, and 11 using a plethysmometer [22].
The percentage inhibition of inflammation was calculated using the 
following formula:
Percentage inhibition = (1 − [Vt/Vc]) × 100
Where Vt represents the change in paw volume in the tested groups and 
Vc represents the change in paw volume in the model group.
Complete Freund’s adjuvant-induced arthritis
Adjuvant arthritis was induced in rats by injecting 100 μL of CFA, 
subplantarly at the right hind paw to all groups, except normal control. 
Rats were pre-treated with test drugs/vehicle for a period of 1 week, 
twice a day before the induction of arthritis, and thereafter, CFA was 
administered and considered as day 0 of the experiment. Paw volume 
was measured at days 0, 4, 8, 12, 16, and 20 following CFA injection 
using a plethysmometer [23].
Biochemical parameters
On the 21st day, blood was collected from animals and used for 
estimation of various biochemical parameters such as serum glutamic 
oxaloacetic transaminase (SGOT), serum glutamic pyruvic transminase 
(SGPT), albumin, calcium, phosphorous, and rheumatoid factor.
Radiographical assessment
After the completion of the study (on day 22), the animals were 
anesthetized using ether and placed on the radiographical plate. X-ray 
analysis of ankle joint of rats from each group was done.
Histopathological study
On day 22, rats were anesthetized and sacrificed using CO2 chamber. 
The ankle joints were amputated and then fixed in 10% neutral buffered 
formalin solution. They were decalcified, sectioned, and stained with 
hematoxylin and eosin and study under the light microscope [24].
Statistical analysis
Values were expressed as mean±standard error of mean (SEM), n=6. All 
the groups were compared with normal control using ANOVA followed 
by Dunnett’s test. Statistically significant values were expressed at 
**p<0.01 and *p<0.05.
RESULTS
In vitro antioxidant assays
Hydrogen peroxide radical scavenging assay
The hydrogen peroxide scavenging activity was recorded in terms 
of percentage inhibition. It was observed that azathioprine and 
pioglitazone showed prominent inhibition of free radicals with 
increased concentrations.
Pioglitazone produced better antioxidant potential than azathioprine. 
The combination of azathioprine and pioglitazone exhibited prominent 
inhibition of hydrogen peroxide radicals, which indicate the synergistic 
effect of the test drugs. The effect of the combination was found to be 
comparable to that of standard ascorbic acid (Fig. 1).
The half-maximal inhibitory concentration (IC50) of azathioprine and 
pioglitazone was found to be 81 and 70, respectively. The IC50 of the 
combination was found to be 56 which was comparable with standard 
ascorbic acid (38) (Fig. 1).
Nitric oxide scavenging activity
The nitric oxide scavenging activity was recorded in terms of percentage 
inhibition. It was observed that azathioprine and pioglitazone have 
shown prominent inhibition of the free radicals.
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The antioxidant property of pioglitazone was found to be better than that 
of azathioprine. The percentage inhibition was increased with increase 
in the concentration of the drug. The combination of azathioprine and 
pioglitazone exhibited significant inhibition of nitric oxide radicals 
which indicates the synergistic effect of the test drugs. The effect of the 
combination was comparable to that of standard ascorbic acid (Fig. 2).
The half-maximal inhibitory concentration (IC50) of azathioprine and 
pioglitazone was found to be 88 and 68, respectively. The IC50 of the 
combination was found to be 59 which was comparable with standard 
ascorbic acid (34) (Fig. 2).
In vitro evaluation of anti-arthritic activity
Inhibition of protein denaturation method
In inhibition of protein denaturation, azathioprine at dose 100 and 
200 µg/mL showed of 49.5% and 68% inhibition, respectively, whereas 
pioglitazone at dose 100 and 200 µg/mL showed of 38% and 58% 
inhibition, respectively.
The combination of above two drugs at a dose of 100 and 200 µg/mL 
showed of 62.5% and 81.6% inhibition, respectively, which was better 
than that of standard indomethacin (Fig. 3).
The percentage inhibition of azathioprine, pioglitazone, their 
combination, and indomethacin at 100 and 200 µg/mL in inhibition of 
protein denaturation method (Fig. 3).
Membrane stabilization method
In membrane stabilization activity, azathioprine showed percent 
inhibition of 58.2% and 82.5% at dose 100 and 200 µg/mL, respectively, 
whereas pioglitazone at dose 100 and 200 µg/mL showed percent 
inhibition of 43.5% and 71.1%, respectively.
The combination of above two drugs at a dose of 100 and 200 µg/mL 
showed percent inhibition of 63.8% and 89.1%, respectively, which was 
better than that of standard indomethacin (Fig. 4).
The percentage inhibition of azathioprine, pioglitazone, their 
combination, and indomethacin at 100 and 200 µg/mL in inhibition of 
membrane stabilization method (Fig. 4).
In vivo evaluation of anti-arthritic activity
Formaldehyde-induced arthritis
Subplantar injection of formaldehyde on the 1st and 3rd days of the 
experiment resulted in significant increase in paw volumes in Group 2 
on days 3, 5, 7, 9, and 11 compared with mean paw volumes of untreated 
control group rats (Group I) (p<0.01). Azathioprine-treated arthritic rats 
(Group 3) shown a significant decrease in mean paw volumes compared 
with the arthritic control group (Group II) (p<0.01). Percent inhibition rates 
of paw volumes were 1.47%, 9.2%, 18.9%, 21%, and 22.5%, respectively.
Pioglitazone-treated arthritic rats (Group IV) show significant 
improvement in mean paw volumes on days 3, 5, 7, 9, and 11 of the 
Fig. 1: Hydrogen peroxide radical scavenging assay of azathioprine, pioglitazone, and their combination
Fig. 2: Nitric oxide scavenging activity of azathioprine, pioglitazone, and their combination
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experiment compared with arthritic control group (Group II) (p<0.05). 
Percent inhibition rates of paw volumes were 0.73%, 7.8%, 14.1%, 
18.7%, and 20.5%, respectively.
Combination of above two drugs produced a better reduction of mean 
paw volumes than individual drugs (p<0.01). Percent inhibition rates 
of paw volumes were 4.4%, 12%, 22.2%, 26.1%, and 34%, respectively. 
The results indicate synergistic interaction between azathioprine and 
pioglitazone (Fig. 5).
Acute treatment with azathioprine (4.5 mg/kg), pioglitazone 
(1.35 mg/kg), their combination (4.5+1.35 mg/kg) and *p˂0.05, 
**p˂0.01 compared with normal, tested by ANOVA followed by 
Dunnett’s test. Data were expressed as mean±SEM (n=6) (Fig. 5).
Complete Freund’s adjuvant-induced arthritis
CFA-induced arthritis in experimental animals is one of the best and 
most widely used animal models since it has a close analogy to human 
rheumatoid disease. The results showed that the paw volume measured 
using plethysmometer gradually increased from the day of injection and 
reached its maximum (3.64 mL) on the 16th day in CFA-induced rats, 
whereas the azathioprine (4.5 mg/kg) and pioglitazone (1.35 mg/kg) 
showed significant decrease in edema volume to about 1.49 and 1.68 mL, 
respectively, on the 20th day as compared to CFA-induced edematous rats. 
Among the drugs azathioprine produced a relatively better effect than 
that of pioglitazone and the combination of these two drugs showed a 
better effect (67.2%) than that of individual drugs (Fig. 6).
Chronic treatment with azathioprine (4.5 mg/kg), pioglitazone 
(1.35 mg/kg), their combination (4.5+1.35 mg/kg) and *p˂0.05, 
**p˂0.01 compared with normal, tested by ANOVA followed by 
Dunnett’s test. Data were expressed as mean±SEM (n=6) (Fig. 6).
Biochemical parameters
SGOT levels measured on day 21 showed higher values in case 
of arthritic group (107.16±0.30) compared to the non-arthritic 
group (62.14±0.47). Treatment with azathioprine and pioglitazone 
significantly reduced the elevated SGOT levels (76±0.55 and 80±0.36) 
compared to arthritic control group. Azathioprine showed relatively 
better effect than pioglitazone. The combination of these two drugs 
showed a significantly better effect than that of individual drugs 
(67±0.44) (p<0.01).
There was a significant rise in SGPT levels of the arthritic group 
(88.16±0.3) compared to the normal group (32.5±0.42). Treatment 
with azathioprine and pioglitazone significantly reduced the elevated 
Fig. 3: Effect of azathioprine, pioglitazone, and their combination using protein denaturation method
Fig. 4: Effect of azathioprine, pioglitazone, and their combination using membrane stabilization method
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SGPT levels (54±0.36 and 61.16±0.47) compared to arthritic control 
group. Azathioprine showed relatively better effect than pioglitazone. 
The combination of these two drugs exhibited a significantly better 
effect than that of individual drugs (41.6±0.4) (p<0.01).
Albumin levels measured on the day 21 significantly showed reduced 
values in the arthritic group (2.34±0.24) compared to the non-arthritic 
group (4.87±0.23). Treatment with azathioprine and pioglitazone 
significantly increased the albumin levels (3.82±0.18 and 4.13±0.21) 
compared to arthritic control group. Pioglitazone showed relatively better 
effect than azathioprine. The combination of these two drugs produced a 
significantly better effect than that of individual drugs (4.52±0.26).
Calcium levels were found to reduce significantly in the arthritic group 
(4.89±0.37) and compared to the non-arthritic group (11.39±0.2). 
Treatment with azathioprine and pioglitazone significantly increased 
the calcium levels (8.68±0.24 and 7.93±0.21) compared to arthritic 
control group. Azathioprine showed relatively better effect than 
pioglitazone. The combination of these two drugs showed a significantly 
better effect than that of individual drugs (9.61±0.51) (p<0.01).
Phosphorous levels were found to significantly reduce in the arthritic 
group (2.53±0.18) compared to the non-arthritic group (7.81±0.19). 
Treatment with azathioprine and pioglitazone significantly increased 
the phosphorous levels (6.02±0.19 and 5.38±0.24) compared to 
arthritic control group. Azathioprine showed relatively better effect than 
pioglitazone. The combination of these two drugs showed a significantly 
better effect than that of individual drugs (7.11±0.25) (p<0.01).
Rheumatoid factor was significantly elevated in the arthritic group 
(18±0.50) and least in the non-arthritic group (8.66±0.17). Treatment 
with azathioprine and pioglitazone significantly decreased the 
Rheumatoid Factor (RF) levels (10.4±0.39 and 12.25±0.22) compared 
to arthritic control group. Azathioprine showed relatively better effect 
than pioglitazone. The combination of these two drugs exhibited a 
significantly better effect than that of individual drugs (9.28±0.21) 
(p<0.01) (Figs. 7 and 8).
Chronic treatment with azathioprine (4.5 mg/kg), pioglitazone 
(1.35 mg/kg), their combination (4.5+1.35 mg/kg), and *p˂0.05, 
**p˂0.01 compared with normal, tested by ANOVA followed by 
Dunnett’s test. Data were expressed as mean±SEM (n=6) (Figs. 7 and 8).
Radiological examinations
The improved anti-inflammatory efficacy of azathioprine in combination 
with pioglitazone was substantiated by radiological examination 
Fig. 5: Effect of azathioprine, pioglitazone, and their combination using formaldehyde-induced arthritis
Fig. 6: Effect of azathioprine, pioglitazone, and their combination using complete Freund’s adjuvant-induced arthritis
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of the animals. Arthritic rats showed bone erosion representing 
bone destruction, mild-to-moderate cartilage damage. This may be 
attributed to chronic exposure of bones to proinflammatory chemical 
mediators such as TNF-α and IL-1, stimulating the enhanced production 
of proteolytic enzymes by chondrocytes resulting in degradation of 
cartilage. In case of azathioprine, pioglitazone, and their combination, 
these changes were observed to have normalized, and the effect of 
combination has protected the joint tissue better than that of individual 
drugs (Fig. 9).
Histopathological studies
There was dense lymphocyte infiltration in subcutaneous fat with focal 
cartilage erosion and foreign-body giant cell reaction in the disease 
control group. There was mild-to-moderate synovial cell hyperplasia 
with pannus formation, and no signs of cartilage erosion in animals 
treated with azathioprine and pioglitazone. There was no synovial cell 
hyperplasia, pannus formation, and cartilage erosion in animals treated 
with both azathioprine and pioglitazone indicating the better effect of 
combination (Fig. 10).
 (a) Joint tissues of normal control rat. Absence of synovial hyperplasia, 
bone erosion, inflammation and cartilage destruction. (b) Joint tissues 
of disease control rat. Dense infiltration of lymphocytes in subcutaneous 
fat focal cartilage erosion and foreign-body giant cell reaction. (c) Joint 
tissues of azathioprine-treated group rat. Mild synovial hyperplasia 
with pannus formation but no signs of cartilage erosion. (d) Joint tissues 
of pioglitazone-treated group. Moderate synovial cell hyperplasia with 
pannus formation and foreign-body giant cell reaction without signs of 
cartilage erosion. (e) Joint tissues of azathioprine+pioglitazone-treated 
group. No synovial cell hyperplasia, pannus formation, and cartilage 
erosion within discriminate focal fat necrosis (Fig. 10).
DISCUSSION
ROS, as well as reactive nitrogen species, can damage basic articular 
constituents either directly or indirectly and lead to the clinical 
expression of inflammatory arthritis. Hydrogen peroxide and nitric 
oxide are major free radicals implicated in the pathogenesis of RA [3]. 
Hence, the antioxidant potential of azathioprine, pioglitazone, and their 
combination was evaluated using hydrogen peroxide and nitric oxide 
radical scavenging activity models.
Hydrogen peroxide, being a weak oxidizing agent, can inactivate few 
enzymes by oxidation of essential thiol (-SH) groups. H2O2 probably 
reacts with Fe2+ and possibly Cu2+ ions to form hydroxyl radical, 
which may produce many of its damaging effects [25]. Azathioprine, 
pioglitazone, and their combination showed prominent hydrogen 
peroxide scavenging activity. The H2O2 scavenging activity of 
azathioprine and pioglitazone might be attributed to the electron 
Fig. 7: Levels of serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transminase in complete Freund’s 
adjuvant-induced arthritis
Fig. 8: Levels of albumin, calcium, phosphorous, and RF in complete Freund’s adjuvant-induced arthritis
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donating nature of mercaptopurine and 2,4-thiozolidinedione, 
respectively, which neutralizes hydrogen peroxide into water.
NO reacts with·O2 radical to form peroxynitrite radicals (ONOO-) that 
damages biomolecules such as proteins, lipids, and nucleic acids [26]. 
During the process of inflammation, cells of the immune system produce 
superoxide radicals by the help of Reduced Nicotinamide Adenine 
Dinucleotide Phosphate (NADPH) oxidase, which plays an important 
role in the induction of vascular complications [27]. Azathioprine and 
pioglitazone significantly inhibit generation of NO and HO radicals in 
a dose-dependent manner. This effect of the test drugs might be due 
to their electron donating nature. The synergistic interaction observed 
with the combination of drugs in both models might be due to the 
combined electron donating nature of the two drugs.
RA is usually characterized macroscopically by paw edema and 
a decrease in body weight. In vitro anti-arthritic activity of the 
azathioprine, pioglitazone, and their combination was carried out by 
the protein denaturation and membrane stabilization method.
Denaturation of protein is a kind of cellular response to various stimuli 
that influence homeostasis. Protein denaturation and macroglobulin 
formation are suggested to cause the protein to become autoantigenic, 
which initiates the immune response and produce biochemical changes 
in connective tissue which ultimately leads to RA [28]. In the present 
study, azathioprine and pioglitazone produced dose-dependent 
inhibition of protein denaturation and its subsequent macroglobulin 
formation and autoantigen production. The combination of the above 
two drugs produced synergistic interaction which might be due to the 
reinforcement of azathioprine action by pioglitazone.
Exposure of RBCs to injurious substances such as hypotonic medium, 
heat, methyl salicylate, or phenylhydrazine results in the lysis of the 
membranes with subsequent hemolysis and oxidation of hemoglobin. 
The inhibition of hypotonicity and heat-induced RBC membrane 
lysis was taken as a measure of the mechanism of anti-inflammatory 
activity because RBC membranes are similar to lysosomal membrane 
components [29]. Both azathioprine and pioglitazone showed 
prominent inhibition of the hemolytic effect of the hypotonic solution 
and its consequent increased permeability caused by inflammatory 
mediators. Combination of the above two drugs produced significant 
and better membrane stabilization due to similarity in the prevention 
of hypotonic solution-induced hemolysis.
In the present study, the anti-arthritic activity of azathioprine, 
pioglitazone, and their combination was evaluated using two in vivo 
experimental models of arthritis, namely formaldehyde and CFA-
induced arthritis.
Formaldehyde develops biphasic localized inflammation. In early 
phase (neurogenic phase), substance P is released, while in the late 
phase (Inflammatory phase), histamine, serotonin, bradykinin, and 
prostaglandins are produced, which results in pronounced vasodilation 
and permeability [30]. The results of the present study showed that 
azathioprine and pioglitazone subdued proliferative edematous 
reaction, which tenably could be due to inhibition of the late phase 
involving the inflammatory mediators. The combination showed 
synergistic effect due to the prominent inhibitory effect on the release of 
inflammatory mediators by preventing activation of macrophage. Thus, 
to further confirm the activity of the test drugs, their efficacy in reducing 
joint inflammation in CFA-induced arthritis in rats was evaluated.
Adjuvant arthritis has been used as a model of subchronic or chronic 
inflammation in rats and is highly relevant to the study of pathophysiology 
and pharmacological control of inflammatory processes, as well as for 
the screening of anti-arthritic drugs [31,32]. CFA produces arthritis in 
two phases – an acute periarticular inflammation followed by a phase 
of bone involvement. It provokes joint swelling, synovial membrane 
inflammation, and cartilage destruction.
Administration of azathioprine and pioglitazone showed significant 
inhibition of paw inflammation, which might be due to their effect 
on the first phase of CFA-induced inflammation, i.e., activation of 
macrophages and the subsequent release of inflammatory mediators. 
Combination of the two drugs produced synergistic effect due to their 
combined inhibitory action on the release of inflammatory cytokines.
RA involves liver and kidney function impairment along with joint tissue 
damage. Under such conditions, there is an increase in serum levels 
of aminotransferases (SGOT and SGPT) due to the cellular release of 
these enzymes from affected tissues. Serum albumin acts as a negative 
acute phase indicator of arthritis both in rats and humans [33]. There 
is reduced calcium and phosphorous which might be due to decreased 
calcitriol and tissue hypoxia due to increased Adenosine Triphosphate 
(ATP) degradation. Hypertrophy and hyperplasia create a hypoxic 
environment in synovial joints, and this was improved significantly on 
azathioprine and pioglitazone treatment [34].
RF is an autoantibody directed against the Fc portion of IgG and serves 
as a key serological marker. It forms immune complexes that contribute 
to the progression of RA [35,36].
The anti-arthritic activity of the test drugs is further depicted by 
reduction of biochemical parameters such as SGOT, SGPT, and 
rheumatoid factor and elevation of serum albumin, calcium, and 
phosphorous.
Fig. 9: Radiographical images of the hind paw radiographical 
images of the hind paw (a) normal rat, (b) diseased rat (arthritis), 
(c) azathioprine-treated rat, (d) pioglitazone-treated rat, 
(e) combination (azathioprine+pioglitazone)-treated rat (Fig. 9)
a b
c d e
Fig. 10: Histopathological studies of rat (a), normal (b), diseased 
(arthritis), (c) azathioprine-treated, (d) pioglitazone-treated, 
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The activity of test compounds was further corroborated by radiological 
and histopathological studies. The possible synergistic interaction might 
be due to the inhibition of the release of matrix metalloproteinases by 
azathioprine and inhibition of inflammatory mediators by pioglitazone 
which together prominently alleviated erosion of cartilage and 
subsequent bone damage (Fig. 11).
Possible mechanism of synergistic interaction between azathioprine 
and pioglitazone (Fig. 11).
CONCLUSIONS
The combination of azathioprine and pioglitazone exhibited significant 
anti-arthritic activity than their counterparts, which might be due to 
their free radical scavenging activity and inhibitory effect on the release 
of inflammatory mediators. This study clearly highlights add on the 
benefit of combination therapy over monotherapy in the management 
of arthritis. This should be further evaluated clinically to prove its 
efficacy in humans, which can result in the development of a better 
remedy for the management of RA.
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